Sökning: WFRF:(Langenskiöld Sophie)
> Wadelius Mia >
Cost-effectiveness ...
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
-
- Verhoef, T. I. (författare)
- UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands
-
- Redekop, W. K. (författare)
- Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
-
- Langenskiöld, Sophie (författare)
- Uppsala universitet,Hälsoekonomi,Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden
-
visa fler...
-
- Kamali, F. (författare)
- Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
-
- Wadelius, Mia (författare)
- Uppsala universitet,Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab
-
- Burnside, G. (författare)
- Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England
-
- Maitland-van der Zee, A-H. (författare)
- Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands
-
- Hughes, D. A. (författare)
- Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, North Wales, Wales
-
- Pirmohamed, M. (författare)
- Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England
-
visa färre...
-
(creator_code:org_t)
- 2016-06-07
- 2016
- Engelska.
-
Ingår i: The Pharmacogenomics Journal. - : Springer Science and Business Media LLC. - 1470-269X .- 1473-1150. ; 16:5, s. 478-484
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas